Notice of Intent to Sole Source - FDA_2272025
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
|---|---|
| State: | Maryland |
| Type of Government: | Federal |
| FSC Category: |
|
| NAICS Category: |
|
| Set Aside: | Total Small Business Set-Aside (FAR 19.5) |
| Posted Date: | Feb 28, 2025 |
| Due Date: | Mar 7, 2025 |
| Solicitation No: | FDA_2272025 |
| Original Source: | Please Login to View Page |
| Contact information: | Please Login to View Page |
| Bid Documents: | Please Login to View Page |
Description
- Contract Opportunity Type: Special Notice (Original)
- Original Published Date: Feb 28, 2025 11:49 am EST
- Original Response Date: Mar 07, 2025 03:00 pm EST
- Inactive Policy: 15 days after response date
- Original Inactive Date: Mar 22, 2025
-
Initiative:
- None
- Original Set Aside: Total Small Business Set-Aside (FAR 19.5)
- Product Service Code: AJ11 - GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH
-
NAICS Code:
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
-
Place of Performance:
Silver Spring , MD 20903USA
The Food and Drug Administration (FDA) intends to award a Sole Source Firm Fixed Price contract order to Emulate Bio at 27 Dry Dock Avenue Boston, Massachusetts 02210
In accordance with FAR Part 6.302-1 (a) (2)(ii) which states” Only one responsible source and no other supplies or services will satisfy agency requirement”.
The purpose of this notice is to inform the public that the Food and Drug Administration (FDA) anticipates issuing a Firm Fixed Price contract.
MINIMUM REQUIREMENTS:
See Attached Statement of Work
This notice is not a request for competitive proposals. However, any party that believes it can meet this requirement as stated herein may submit a written capability statement that clearly supports and demonstrates their ability to perform the requirement.
Capability statements must be received by the response date and time of this notice. Submissions will be reviewed to determine if they can meet the requirement. A determination by the Government to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government.
It is anticipated that an award will be issued to Emulate Bio within approximately ten (10) days after the date of this notice unless the Government determines that any other organization has the capability to meet this requirement.
Response Date: March 7, 2025, by 3.00PM EST. Please email responses to Hilda Aryeh –hilda.aryeh@fda.hhs.gov.
- 5630 Fishers Lane
- Rockville , MD 20841
- US
- HILDA ARYEH
- hilda.aryeh@fda.hhs.gov
- Feb 28, 2025 11:49 am ESTSpecial Notice (Original)
See Also
Follow Notice of Intent to Sole Source the Co-sponsorship of a Forum on
DEPT OF DEFENSE
Due by 11/18/2026
Follow Strategic Contract Consolidation Announcement Active Contract Opportunity Notice ID Command_Control_and_Information_Network_(CPE_C2IN) Related Notice
DEPT OF DEFENSE
Follow Generative Unconstrained Intelligence Drug Engineering (GUIDE) collaboration between U.S. interagency, academic and
DEPT OF DEFENSE
Due by 10/18/2028
Follow Broad Agency Announcement DEVCOM C5ISR RTI Active Contract Opportunity Notice ID W56KGU23RRTID
DEPT OF DEFENSE
Due by 10/31/2027